NDLI: Hematological toxicity of carboplatin for gynecological cancer according to body mass index

Please wait, while we are loading the content...

The effectiveness of i.v. cefuroxime prophylaxis of surgical site infection after elective inguinal hernia repair with mesh: A retrospective observational study

First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action

Comparative efficacy of nonhormonal drugs on menopausal hot flashes

Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial

Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor

Hair analysis for detection of triptans occasionally used or overused by migraine patients—a pilot study

Hematological toxicity of carboplatin for gynecological cancer according to body mass index

Pharmacokinetic patterns of risperidone-associated adverse drug reactions

Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid—a large-scale study based on naturalistic therapeutic drug monitoring data

A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction

Polypharmacy and medication regimen complexity as factors associated with staff informant rated quality of life in residents of aged care facilities: a cross-sectional study

Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?

Development of a quality instrument for assessing the spontaneous reports of ADR/ADE using Delphi method in China

Deferasirox AUC efficacy cutoff and role of pharmacogenetics

Carriers of genetic variants in the HNF1A gene are more common among dead opioid addicts than among living addicts

European Journal of Clinical Pharmacology : Volume 72, Issue 7, July 2016

European Journal of Clinical Pharmacology : Volume 72, Issue 6, June 2016

European Journal of Clinical Pharmacology : Volume 72, Issue 2, February 2016

European Journal of Clinical Pharmacology : Volume 67

European Journal of Clinical Pharmacology : Volume 62

European Journal of Clinical Pharmacology : Volume 57

Hematological toxicity of carboplatin for gynecological cancer according to body mass index

Content Provider	Springer Nature Link
Author	Gutierrez, Fernando Gonzalez de la Fuente, Guillermo Antonio Nazco, Gloria Julia Oramas, Juana Batista, rberto
Copyright Year	2016
Abstract	The aim of the present study was to analyze how patient weight affects the hematological toxicity of carboplatin and whether this toxicity is more prevalent in overweight patients.We performed a retrospective 2-year study of patients diagnosed with a gynecological cancer and whose treatment regimen contained carboplatin (AUC dose = 5 or 6) and paclitaxel (dose = 175 mg/m2) every 3 weeks (CP scheme). We recorded all severe hematological events (thrombocytopenia, neutropenia, and/or anemia grade III/IV) according to the CTCAE v4.03, as well as treatment modifications and the need for granulocyte colony-stimulating factors (G-CSF) and/or erythropoietin (EPO) or packed red blood cells (PRBC). Patients with a body mass index (BMI) ≥27 kg/m2 were considered as overweight (OW) and those with a BMI <27 kg/m2 were considered as normal weight (NW).Fifty-two patients met the inclusion criteria (21 patients in the OW group, 31 patients in the NW group). The OW group showed a higher incidence of thrombocytopenia (95% confidence intervals (CI) 1.51–27.72; p < 0.02) and anemia (95% CI 1.06–33.63; p < 0.05). Moreover, this was reflected in a greater number of changes in the usual CP regimen (95% CI 2.19–44.32; p < 0.01). The need for G-CSF and/or EPO/PRBC was also significantly higher in the OW group (95% CI 1.08–12.16; p < 0.04).Carboplatin dosing based on real weight in obese patients resulted in increased hematologic toxicity, mainly thrombocytopenia. Dose adjustment based on other descriptors of weight, such as adjusted weight, may be better tolerated by patients. However, future studies are needed to demonstrate not only better safety of carboplatin but also improved survival rates.
Starting Page	1083
Ending Page	1089
Page Count	7
File Format	PDF
ISSN	00316970
Journal	European Journal of Clinical Pharmacology
Volume Number	72
Issue Number	9
e-ISSN	14321041
Language	English
Publisher	Springer Berlin Heidelberg
Publisher Date	2016-06-10
Publisher Place	Berlin, Heidelberg
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Carboplatin Ovarian cancer Hematological toxicity Pharmacology/Toxicology
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index

Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.

Influence of body mass index on prognosis in gynecological malignancies

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles.

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

Hematological toxicity of carboplatin for gynecological cancer according to body mass index

Similar Documents

Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index

Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.

Influence of body mass index on prognosis in gynecological malignancies

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles.

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

Hematological toxicity of carboplatin for gynecological cancer according to body mass index